Skip to content

Vascular Lab Resource (VLR) Biorepository

Vascular Lab Resource (VLR) Biorepository Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05628948
Enrollment
500
Registered
2022-11-29
Start date
2019-11-14
Completion date
2031-06-30
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Disease, Arterial Dissection, Cardiovascular Diseases, Carotid Disease, Fibromuscular Dysplasia, Lipedema, Lymphedema, May-Thurner Syndrome, Metabolic Disease, Non-Atherosclerotic Chronic Arterial Occlusive Disease, Peripheral Artery Disease, Thoracic Outlet Syndrome, Thrombosis, Vasculitis, Vasospasm, Venous Disease

Brief summary

This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.

Detailed description

We are proposing a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration. The care of subjects with vascular and metabolic diseases is very fragmentary, and they remain underserved clinically and under-studied. We will capitalize on the highly collaborative clinical environment in HVI and other clinical institutes to develop and constantly utilize a vascular biobank. This protocol will study blood, urine, and/or stool samples and clinical data from subjects with cardiovascular and/or metabolic diseases including: peripheral artery disease, carotid disease, aneurysmal disease, chronic venous disease, thrombosis, lymphedema and lipedema, non-atherosclerotic arterial stenosis (vasculitis, fibromuscular dysplasia, arterial dissection and aneurysmal disease, May-Thurner Syndrome etc.), compressive and spastic disorders (thoracic outlet syndrome, vasospasm). This initiative will allow for the opportunity to explore pathways of thrombosis, inflammation, gut microbiome, alterations in cell signaling, lipid metabolism and other metabolic pathways in vascular diseases. Further, this study will enhance and expand ongoing efforts in the Vascular Lab to collect data for the purpose of quality control and safety. The specimen sample collection will enable biochemical and genetic testing on participants once sufficient numbers are attained.

Interventions

None listed

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. 18 years or older 2. Subjects capable of providing informed consent document 3. Subjects with diagnosed with or at risk for cardiovascular and metabolic diseases

Exclusion criteria

1. Known life expectancy of ≤ 6 months at the time of enrollment 2. Known current pregnancy 3. Severe Anemia (last documented hemoglobin \< 7.0 g/dL)

Design outcomes

Primary

MeasureTime frameDescription
To collect blood, urine, and/or stool samples for biorepository10 yearsTo explore pathways of thrombosis, inflammation, gut microbiome, alterations in cell signaling, lipid metabolism and other metabolic pathways in vascular diseases

Countries

United States

Contacts

Primary ContactScott Cameron, MD, PhD
cameros3@ccf.org216-444-1680

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026